logo
Teen found unresponsive in room 'shouldn't have been alone', Essex mental health trust tells inquest

Teen found unresponsive in room 'shouldn't have been alone', Essex mental health trust tells inquest

ITV News29-04-2025
An NHS trust has admitted a teenage girl found dead in her hospital room should not have been allowed to return there unsupervised.
Elise Sebastian was just 16 when she took her own life while being treated at a mental health unit in Essex in 2021.
At the start of the inquest into her death, the trust that runs the St Aubyn Centre in Colchester told the jury that Elise had been able to return to her room unaccompanied on 17 April 2021, despite being on observation at the time.
The teenager was later found unresponsive, was resuscitated and taken to Colchester Hospital, where she died two days later.
Pravin Fernando, representing Essex Partnership University NHS Trust, admitted Elise's room should have been locked to prevent her entering alone, adding: "The trust accepts that these failings were causative of her death."
Elise had a history of mental ill health which dated back to 2016 when she was 12 and included anxiety and depression.
She was diagnosed with high-functioning autistic spectrum disorder in March 2020 and, while an inpatient at mental health units, including St Aubyn, had previously self-harmed and absconded.
But in statements read to Essex Coroner's Court, Elise's parents described her as a "happy, outgoing, funny little girl" who loved music, reading and art.
Her mum, Victoria Sebastian, said she had visited her daughter - who was the youngest of four siblings - the same day she was found unresponsive and Elise had been "so excited to see me".
As a photograph of the teenager was passed around court, Mrs Sebastian talked about her daughter's love of One Direction and her plans to work with animals.
"She was my beautiful baby, my best friend," she told the jury. "It was very hard as a mother to watch her struggle."
Her dad, Glen Sebastian added: "My world has been completely destroyed. My family has been shattered. I've hardly left the house in the past couple of years."
The court was told the inquest, which is due to last around a month, was likely to look at a range of issues including the appropriateness of care plans and risk assessments, staffing levels, training and the management of Elise's self-harming.
On the opening day, the hearing also heard from a paramedic with the East of England Ambulance Service who described the call-out to the St Aubyn Centre as "frustrating", having had to wait for a member of staff to unlock each door he passed through.
Lisa Cunningham, an Essex and Herts Air Ambulance doctor who arrived at the centre around 7.30pm, said staff seemed stressed and it was difficult to get information from them.
Essex Partnership University Trust is currently the subject of a statutory inquiry which is looking into the deaths of more than 2,000 patients - including Elise - in its care between January 2000 and December 2023.
The Lampard Inquiry will include those who died within three months of discharge, and those who died as inpatients receiving NHS-funded care in the independent sector.
At a hearing last year the chairwoman of the inquiry, Baroness Kate Lampard, said 'we may never know' the true number of people who died.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Derby doctor's errors examined after 101 patient deaths
Derby doctor's errors examined after 101 patient deaths

BBC News

timean hour ago

  • BBC News

Derby doctor's errors examined after 101 patient deaths

Errors made by a doctor are being reviewed to establish whether they played a part in the deaths of 101 patients.A former radiology consultant at Royal Derby Hospital has been under review, over cardiac MRI (magnetic resonance imaging) scans, since concerns were raised by cardiology colleagues in November 2020. Documents seen by the Local Democracy Reporting Service (LDRS) showed 1,224 cases between 2013 and 2020, involving the doctor, were looked into as part of the review. The University Hospitals of Derby and Burton NHS Foundation Trust claimed it took an "open and transparent" approach with the public in regards to the review and that "no significant harm" had been identified so far. The initial review – due to be published in full later this year – found while there is an expected discrepancy rate of 5% for cardiac MRI scans, an audit of 63 cases found the doctor's discrepancy rate was 37%. That meant it was seven times the accepted rate, presenting an error with one out of every three scans.A discrepancy rate across the whole 1,224 cases has not been provided. Evidence of 'misdiagnosis' The ongoing review found that out of the 1,224 cases, two cases were found to show "definite omission or misinterpretation with unequivocal potential for serious morbidity or threat to life". Of the cases reviewed, 102 were found to show "definite omission or interpretation of finding with strong likelihood of moderate morbidity but not threat to life".Meanwhile, in 361 cases, "clinical significance of disagreement is debatable or likelihood of harm is low", and in 378 cases there was "disagreement over style and/or presentation of the report including failure to describe insignificant features".A total of 176 patients out of the 1,224 assessed have now died, with a "misreported" cardio MRI scan found in 101 of those patients. The medical examiner will now assess if any of the 101 deceased patient cases showed evidence that their misreported MRI, or any associated subsequent treatment delay, was "likely" to or "could" have "contributed to", "caused" or "accelerated" their patients were contacted by the trust. A total of 120 patients had their cases recalled by the trust for further assessment with evidence of "misdiagnosis" "which will have impacted treatment decisions and pathways".The hospital trust apologised for the impact on patients and indicated training and processes were at fault, but said changes had been made. 'Choices taken away' The review into the doctor was due to conclude in January, then believed to have then shifted to April and is still affected patient, who was seen by the doctor in 2014, called the matter a "monumental failure to manage from trust leadership" and said the review had been badly handled. She said she was notified about her misreported MRI nine years after the scan."We are not going to get the full picture because of how long it has taken. They haven't considered the future prognosis for patients."Nurses rely on diagnoses and care plans and there is potential care here that has not been given."This has taken away my choices. Because I didn't have that knowledge, I couldn't make decisions based on correct information and the people treating me couldn't make correct decisions either because of the misreporting of a scan."It is really, really upsetting."Karen Reynolds, a clinical negligence lawyer at Freeths in Derby, who is representing the patient, added she was "shocked" the review had not come to light sooner. "The trust must now be entirely transparent about this review," she said. "It is their responsibility to uphold the duty of candour and do what they can to reassure patients." The trust said the doctor had left the organisation, adding "no concerns have been found about the individual's other areas of practice".The General Medial Council (GMC) - which regulated doctors - confirmed the doctor was still registered with a licence to practise with no fitness to practise case has been brought before the Medical Practitioners Tribunal Service by the GMC, the MPTS trust said those involved in reviewing the case at the time - which included colleagues external to the organisation - decided it did not meet GMC referral Gis Robinson, the trust's executive chief medical officer, said: "We have re-seen and personally apologised to the 120 patients who have needed to be followed up as part of this review, and while so far the investigation has found no significant harm has been caused, we absolutely apologise again to those affected for the emotional impact this has had and for the extended time this has taken."Though scans are just one of many elements we use to diagnose a patient and variations in how clinicians read them are expected, our investigation has shown our processes were not as strong as they could have been and we have made changes – with scans now being reviewed as part of a multidisciplinary team, and a percentage of scans externally audited as an additional safety measure."Our priority has understandably been communicating with and supporting those who have been directly affected as we have moved through this process, and we will publish a public report as we normally would once the investigation in complete."

Covid XFG cases rising: What is known about new strain
Covid XFG cases rising: What is known about new strain

North Wales Chronicle

time2 hours ago

  • North Wales Chronicle

Covid XFG cases rising: What is known about new strain

Covid XFG, or 'stratus' as it is also known, is a descendant of the Omicron variant and was first detected back in January 2025. It has also been referred to as a "Frankenstein" or "recombinant" strain. Today, WHO's Scientific Advisory Group on the Origins of Novel Pathogens (SAGO), a group convened by WHO, released a report on the origins of SARS-CoV-2, the virus that caused the #COVID19 pandemic. For this report, SAGO reviewed peer-reviewed papers and reviews, as well as… "This means it emerged when a person was infected with two Covid strains at once which then became a new hybrid variant," The Mirror explained. Reports of the new variant are "growing rapidly", according to the World Health Organisation (WHO), and it is showing some signs of "additional immune evasion" compared to others. The WHO has placed Covid stratus "under monitoring" due to the rise in cases worldwide. It is one of seven COVID-19 variants currently being monitored, along with the NB.1.8.1 strain, which is the dominant variant worldwide. The coming COVID-19 Winter Surge in Australia will show the world where we are actually headed is happening in South-Eats Asia and East Asia are just the 'preludes'...watch how NB.1.8.1 spawns are evolving including PQ.1, PQ.2 and even sub-lineages like PE.1. However, the WHO stated that the risk posed by the new variant was "low," and that approved COVID-19 vaccines are expected to be effective against it. The world health experts, in a recent risk evaluation, said: "Several countries in the South-East Asia Region have reported a simultaneous rise in new cases and hospitalisations, where XFG has been widely detected. "Current data do not indicate that this variant leads to more severe illness or deaths than other variants in circulation." The WHO added: "The available evidence on XFG does not suggest additional public health risks relative to the other currently circulating Omicron descendent lineages." Covid Stratus has already been detected in 38 different countries around the world. The WHO added: "The detection of XFG is increasing across several countries in various regions that are consistently sharing SARS-CoV-2 sequences with stable to slightly increasing trend in viral activity and hospitalizations." The new Stratus strain of Covid is currently the "most prevalent" in the UK, according to the UK Health Security Agency (UKHSA). Health organisations are yet to list any symptoms unique to Covid Stratus. However, common symptoms of other COVID-19 variants, according to the NHS, include: COVID-19 vaccines are available in the UK, and are usually offered on the NHS in spring and early winter. The vaccine is available for those: RECOMMENDED READING: The common disease medical experts believe will cause the next global pandemic Am I eligible for free prescriptions? Yes, if you have 1 of these 11 conditions The 6 beers that are good for your health (and the ones to avoid) The NHS said: "The COVID-19 vaccines are offered because viruses change and protection fades over time. It's important to top up your protection if you're eligible." The vaccine helps: Eligible people can book in for a vaccination via the NHS website, the NHS App, or by attending a walk-in COVID-19 vaccination site.

Katie Price warns 'Harvey's going to look different' as she issues health update
Katie Price warns 'Harvey's going to look different' as she issues health update

Daily Mirror

time2 hours ago

  • Daily Mirror

Katie Price warns 'Harvey's going to look different' as she issues health update

Katie Price has disclosed that "a lot's gonna change" for her son, Harvey, who will "look different" when he starts a new medication. In a recent episode of The Katie Price Show, the former glamour model, who was broadcasting from Dubai, revealed that her son, Harvey Price, is set to switch from college to independent living. Katie decided to place Harvey, who has ADHD, autism, Prader-Willi Syndrome, and septo-optic dysplasia, into full-time care in a residential college in 2021 so he could learn new skills and become more independent. In July 2024, she revealed that she was forced to take Harvey out of his £350,000-per-year college, as the local authority wouldn't pay for him because he was deemed to have "no healthcare issues". Katie has now revealed that Harvey is due to start taking the weight-loss drug Mounjaro and will attend a place in Southampton that helps people living with Prader-Willi Syndrome. She said: "And they've had a few people there, within months, just losing weight because they know how to deal with it. "You know, in a couple of years, Harvey's gonna look different with that place... the Mounjaro, like? And then he gets the proper little life back, because at the moment, where he's so big, he's just out of breath. So, a lot's gonna change for Harv when he moves. "I don't... I can't wait to see what he's gonna look like. Because everyone's so used to Harvey being so big — imagine him being a lot smaller. It'll be so weird." Mounjaro, the brand name for tirzepatide, is an antidiabetic medication that was approved by the National Institute for Health and Care Excellence (NICE) in 2024 for the treatment of obesity on the NHS. As of last month, GPs across England could prescribe the drug to severely obese people for this purpose, initially to those with a BMI score of more than 40 during the first year. Patients who can access the medication will also have other long-term health conditions, including high blood pressure (otherwise known as hypertension), type 2 diabetes, dyslipidaemia, or sleep apnoea. It's believed that about 1.5 million people take weight loss drugs across Britain, although much of this is via private prescriptions or through dedicated weight loss services. According to the NHS, as with all medications, tirzepatide can have side effects, including nausea, indigestion, constipation, and diarrhoea. More serious side effects could include pancreatitis, low blood sugar, and gallstones. Speaking about the rollout, Dr Claire Fuller, from NHS England, said: "This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today. "We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health, and greater access to weight loss drugs will make a significant difference to the lives of those people."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store